Science

Scientists demonstrate AI-designed enzyme for drug synthesis

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 23/10/2026, 21:10:24 UTC.

Briefings

Scientists at the Institute for Protein Design (IPD) in collaboration with NVIDIA developed the RFD4-Proteina, a unified generative model designed to create entirely new protein sequences and structures. This system achieves computational design success rates five to 10 times higher than previous models and generates candidate sequences five to 10 times faster, marking a significant leap in AI-driven drug synthesis capabilities.

Key points

• The RFD4-Proteina model was developed by the Institute for Protein Design (IPD) in collaboration with NVIDIA.
• The system achieves computational design success rates five to 10 times higher than previous models.

Context

This breakthrough represents a major advancement in AI-driven drug synthesis, allowing researchers to design entirely new protein sequences and structures using advanced generative models.

Limitations

Evidence is limited to the specific performance metrics of the RFD4-Proteina model; no data on clinical trials, long-term stability, or specific drug candidates is provided.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 23/10/2026, 21:11:39 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeied4mx7z4vcjxuu36fwlno6off56rxhr2ndh3d2hgkib7bvhhqxhy